There are nine specific key genes driving paclitaxel resistance in cancer cells, including microfibril-associated protein 2 (MFAP2), membrane metalloendopeptidase (MME), inhibin subunit beta A (INHBA), claudin 1 (CLDN1), putative homeodomain transcription factor 2 (PHTF2), tetraspanin 9 (TSPAN9), MLLT11 transcription factor 7 cofactor (MLLT11), chemokine (C-C motif) ligand 26 (CCL26), and glycosyltransferases (KDELC1) gene (Fig. 6) [85]. This evidence concerns the gene MLLT11 and cancer.